NVCR
NovoCure Limited
$17.89
+6.30%
2026-05-08
About NovoCure Limited
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
Key Fundamentals
Forward P/E
-14.50
EPS (TTM)
$-1.53
ROE
-50.0%
Revenue Growth (YoY)
12.3%
Profit Margin
-25.7%
Debt/Equity
71.04
Price/Book
5.61
Beta
0.90
Market Cap
$1.97B
Avg Volume (10D)
2.4M
Recent Breakout Signals
No recent breakout signals detected for NVCR.
Recent Price Range (60 Days)
60D High
$18.19
60D Low
$10.14
Avg Volume
1.9M
Latest Close
$17.89
Get breakout alerts for NVCR
Sign up for Breakout Scanner to receive daily notifications when NVCR triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
NovoCure Limited (NVCR) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors NVCR daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. NVCR operates in the Healthcare sector within the Medical Devices industry. Data is provided for informational purposes only and does not constitute financial advice.